Plasmagen Biosciences taps into niche Indian biopharma market with launch of CSL’s Haemocomplettan P

20 June 2024 | News

Haemocomplettan® P will cater to the 1,50,000 cardiac surgeries and over 1,800 liver transplant patients

Plasmagen Biosciences, headquartered in Bengaluru, specialising exclusively in Plasma Protein and Speciality Care Therapy, has recently announced the launch of Haemocomplettan® P (Human Fibrinogen Concenrate), manufactured by CSL Behring, a business unit of global biotechnology leader CSL.

Plasmagen is CSL Behring’s exclusive distributor of Haemocomplettan® P in India. Haemocomplettan® P is approved for therapy and prophylaxis of haemorrhagic diatheses in congenital afibrinogenaemia and acquired hypofibrinogenaemia.

Due to the high burden of uncontrolled massive bleeding in cardiac and liver transplant surgeries, there is an immense need for a product like Haemocomplettan® P in India. Therefore, Plasmagen pursues a vision of ushering in these niche therapy segments with products like haemocomplettan® P.

With approximately 1,50,000 cardiac surgeries and around 1,800 liver transplants being performed in India every year, there is a huge need for such therapies in the country. Approximately 1 out of every 2 cardiac surgery patients requires blood transfusion to manage haemorrhage, and over 25% of blood transfusions in hospitals are for liver transplant recipients and Haemocomplettan® P could be used specially for massive haemorrhagic cases.



× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account